Literature DB >> 3005330

Influence of urapidil on alpha- and beta-adrenoreceptors in pithed rats.

K H Sanders, U Kilian, N Kolassa, W Schoetensack.   

Abstract

The interaction of urapidil with pre- and postsynaptic alpha-adrenoreceptors and with postsynaptic beta-adrenoreceptors was studied in pithed normotensive rats and compared to the effects of clonidine, prazosin, and atenolol. I.v. injection of urapidil did not substantially change blood pressure, while clonidine raised blood pressure. Urapidil dose-dependently antagonized the pressor effects of the alpha 1-agonist L-phenylephrine (pDR2 6.8) and of the alpha 2-agonist azepexole (pDR2 5.2). Compared to urapidil, prazosin was a more potent antagonist of phenylephrine at postsynaptic vascular alpha 1-adrenoreceptors (pDR2 8.7) and of azepexole at alpha 2-adrenoreceptors (pDR2 5.6). Urapidil inhibited the tachycardia produced by discontinuous or continuous electrical stimulation of the thoracic spinal outflows (ID50 4.8 and 27.2 mumol/kg, respectively). In contrast to the inhibitory action of clonidine (ID50 0.039 and 0.023 mumol/kg, respectively), the inhibition by urapidil was not reversed by the selective alpha 2-antagonist rauwolscine (10 mumol/kg). Prazosin did not change stimulation-evoked tachycardia but atenolol caused pronounced inhibition (ID50 0.158 mumol/kg, discontinuous stimulation). Urapidil dose-dependently antagonized the tachycardic effect of isoprenaline at beta 1-adrenoreceptors (pDR2 5.1) but also exhibited intrinsic activity by increasing basal heart rate (maximum effect of urapidil was 30% of that of isoprenaline). Urapidil did not change the vasodilatory beta 2-adrenoreceptor-mediated effect of isoprenaline. The results suggest that urapidil is an antagonist at postsynaptic vascular alpha 1- and alpha 2-adrenoreceptors, with a greater potency against alpha 1-adrenoreceptors. An agonistic interaction of urapidil with presynaptic alpha 2-adrenoreceptors could not be demonstrated in pithed rats. Instead, the inhibition by urapidil of stimulation-evoked tachycardia could be accounted for by its beta 1-adrenoreceptor antagonistic effect.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3005330     DOI: 10.1111/j.1474-8673.1985.tb00555.x

Source DB:  PubMed          Journal:  J Auton Pharmacol        ISSN: 0144-1795


  8 in total

1.  Acute effects of urapidil on airway response in hypertensive patients with chronic obstructive pulmonary disease.

Authors:  M Cazzola; A Spinazzi; G Santangelo; V W Steinijans; W Wurst; P Solleder; G Girbino
Journal:  Drugs       Date:  1990       Impact factor: 9.546

2.  The effect of urapidil on responses to phenylephrine, angiotensin and isoprenaline in man.

Authors:  B Tomlinson; J C Renondin; B R Graham; B N Prichard
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Human pharmacology of urapidil.

Authors:  A M Shepherd
Journal:  Drugs       Date:  1988       Impact factor: 9.546

4.  Effect of urapidil on the performance of ischemic myocardium in anesthetized dogs.

Authors:  H Schad; W Heimisch; A Barankay; S Hesse; N Mendler
Journal:  Basic Res Cardiol       Date:  1990 May-Jun       Impact factor: 17.165

5.  Acute haemodynamic effects of urapidil in patients with chronic left ventricular failure.

Authors:  U Tebbe; W Wurst; K L Neuhaus
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 6.  Clinical pharmacokinetics of urapidil.

Authors:  R Kirsten; K Nelson; V W Steinijans; K Zech; R Haerlin
Journal:  Clin Pharmacokinet       Date:  1988-03       Impact factor: 6.447

Review 7.  Urapidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.

Authors:  H D Langtry; G J Mammen; E M Sorkin
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

8.  Urapidil and some analogues with hypotensive properties show high affinities for 5-hydroxytryptamine (5-HT) binding sites of the 5-HT1A subtype and for alpha 1-adrenoceptor binding sites.

Authors:  G Gross; G Hanft; N Kolassa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-12       Impact factor: 3.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.